Superluminal Medicines Inc.’s cover photo
Superluminal Medicines Inc.

Superluminal Medicines Inc.

Biotechnology Research

Boston, Massachusetts 2,544 followers

Generative biology and chemistry company revolutionizing the speed and accuracy of how medicine is created.

About us

Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Our discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability. With a lead program candidate expected in the near term, our proprietary pipeline validates our platform with initial programs focused on high-value GPCR targets. We’re pleased to be backed by a strong network of investors including RA Capital Management, Insight Partners, NVentures, Catalio Capital Management, Eli Lilly and Company, Gaingels, and Cooley LLP.

Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
Boston, Massachusetts
Type
Privately Held

Locations

  • Primary

    15 Necco St

    Lilly Gateway Labs, 4th Floor

    Boston, Massachusetts 02210, US

    Get directions

Employees at Superluminal Medicines Inc.

Updates

Similar pages

Browse jobs

Funding